---
title: "Bank of America Securities Remains a Buy on Ceribell, Inc. (CBLL)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286673817.md"
description: "Bank of America Securities has maintained a Buy rating on Ceribell, Inc. (CBLL), with shares closing at $16.30. Analyst Travis Steed highlights a Strong Buy consensus with a $28.50 average price target, indicating a 74.85% upside. Ladenburg Thalmann & Co. also reiterated a Buy rating with a $32.00 target."
datetime: "2026-05-17T13:25:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286673817.md)
  - [en](https://longbridge.com/en/news/286673817.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286673817.md)
---

# Bank of America Securities Remains a Buy on Ceribell, Inc. (CBLL)

In a report released on May 15, Travis Steed from Bank of America Securities maintained a Buy rating on Ceribell, Inc.. The company’s shares closed last Friday at $16.30.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Steed covers the Healthcare sector, focusing on stocks such as Stryker, Boston Scientific, and Medtronic. According to TipRanks, Steed has an average return of \-0.2% and a 45.71% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ceribell, Inc. with a $28.50 average price target, representing a 74.85% upside. In a report released on May 12, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $32.00 price target.

### Related Stocks

- [CBLL.US](https://longbridge.com/en/quote/CBLL.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [SYK.US](https://longbridge.com/en/quote/SYK.US.md)
- [BSX.US](https://longbridge.com/en/quote/BSX.US.md)
- [MDT.US](https://longbridge.com/en/quote/MDT.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Ceribell files Form 3 initial beneficial ownership statement for director Sharon O’Keefe](https://longbridge.com/en/news/294427776.md)
- [Ceribell wins CMS NTAP for delirium monitor, worth up to $2,171 per Medicare case](https://longbridge.com/en/news/294682766.md)
- [H.C. Wainwright Keeps Their Buy Rating on Compugen (CGEN)](https://longbridge.com/en/news/294794759.md)
- [Goldman Sachs Sticks to Their Buy Rating for MERLIN Properties SOCIMI SA (MRPRF)](https://longbridge.com/en/news/294773638.md)
- [RBC Capital Keeps Their Buy Rating on Bausch + Lomb Corporation (BLCO)](https://longbridge.com/en/news/294530387.md)